ISSN:1173-8324    

出版商:ADIS    

年代:1997

数据来源: ADIS

摘要:

Why do some patients with follicular B-cell lymphoma go into spontaneous remission with no therapy, only to relapse at a later date and ultimately die of their disease? One theory is that some as yet unidentified immune system regulator is briefly activated, making the patient symptom-free for a time even though tumour cells can still be found in the bone marrow. Researchers seeking an immunological therapy have developed vaccines against the malignant B cells with some success, but the vaccines are very expensive and large quantities are required. A better approach may be customised vaccination using ‘naked DNA’ isolated from the malignant B cell itself, or by using the patient's biopsy specimen as the vaccine ‘starter’. These ideas were discussed at the 33rd Annual Meeting of the American Society of Clinical Oncology [Denver, US; May 1997].

ISSN:1173-8324    

出版商:ADIS    

年代:1997

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1997

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1997

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1997

数据来源: ADIS

摘要:

Research involving the use of cytokine therapy to treat sepsis and septic shock is still underway despite disappointing clinical results with the use of monoclonal antibodies against tumour necrosis factor (TNF) in patients with sepsis. Knoll believes that the key to success with cytokine therapy in these indications may lie with appropriate patient selection. The company has evidence from early clinical trials that therapy with an anti-TNF monoclonal antibody will only benefit those patients with sepsis who have elevated plasma levels of interleukin-6 (IL-6). This notion is being investigated in a phase III study. The details of the trial were presented at the 7th International IBC Conference on Sepsis [Washington, US; April 1997]. In another development, Bayer is investigating the effects of its anti-TNF monoclonal antibody in patients with septic shock, while Cytokine Network has developed an agent that inhibits multiple pro-inflammatory cytokines by acting at an early stage of the cytokine cascade.

ISSN:1173-8324    

出版商:ADIS    

年代:1997

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1997

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1997

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1997

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1997

数据来源: ADIS